These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 9336745)

  • 1. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
    Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
    Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
    Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
    Yannelli JR; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg SA
    Int J Cancer; 1996 Feb; 65(4):413-21. PubMed ID: 8621219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.